Citadel Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.68M | Buy |
13,400
+6,000
| +81% | +$1.19M | ﹤0.01% | 5492 |
|
|
2025
Q4 | $1.4M | Buy |
7,400
+600
| +9% | +$115K | ﹤0.01% | 6660 |
|
|
2025
Q3 | $1.2M | Buy |
6,800
+3,300
| +94% | +$491K | ﹤0.01% | 7137 |
|
|
2025
Q2 | $398K | Buy |
3,500
+800
| +30% | +$85.5K | ﹤0.01% | 9157 |
|
|
2025
Q1 | $284K | Sell |
2,700
-10,100
| -79% | -$1.14M | ﹤0.01% | 9726 |
|
|
2024
Q4 | $1.37M | Buy |
12,800
+2,000
| +19% | +$226K | ﹤0.01% | 6398 |
|
|
2024
Q3 | $1.08M | Sell |
10,800
-15,300
| -59% | -$1.54M | ﹤0.01% | 6726 |
|
|
2024
Q2 | $2.2M | Buy |
26,100
+1,700
| +7% | +$135K | ﹤0.01% | 5135 |
|
|
2024
Q1 | $1.78M | Buy |
24,400
+11,400
| +88% | +$840K | ﹤0.01% | 5748 |
|
|
2023
Q4 | $928K | Buy |
13,000
+7,700
| +145% | +$454K | ﹤0.01% | 6823 |
|
|
2023
Q3 | $318K | Sell |
5,300
-600
| -10% | -$39.5K | ﹤0.01% | 9063 |
|
|
2023
Q2 | $425K | Buy |
5,900
+900
| +18% | +$67.5K | ﹤0.01% | 8292 |
|
|
2023
Q1 | $368K | Sell |
5,000
-1,800
| -26% | -$128K | ﹤0.01% | 8957 |
|
|
2022
Q4 | $454K | Sell |
6,800
-269,557
| -98% | -$17.5M | ﹤0.01% | 8446 |
|
|
2022
Q3 | $14.8M | Buy |
276,357
+260,487
| +1,641% | +$15.3M | ﹤0.01% | 2234 |
|
|
2022
Q2 | $883K | Buy |
15,870
+5,130
| +48% | +$291K | ﹤0.01% | 7309 |
|
|
2022
Q1 | $754K | Sell |
10,740
-12,504
| -54% | -$907K | ﹤0.01% | 8384 |
|
|
2021
Q4 | $2.24M | Sell |
23,244
-8,816
| -27% | -$814K | ﹤0.01% | 5982 |
|
|
2021
Q3 | $2.79M | Buy |
32,060
+4,809
| +18% | +$372K | ﹤0.01% | 5541 |
|
|
2021
Q2 | $2.23M | Sell |
27,251
-51,296
| -65% | -$4.27M | ﹤0.01% | 6324 |
|
|
2021
Q1 | $7.47M | Sell |
78,547
-168,315
| -68% | -$15.9M | ﹤0.01% | 3456 |
|
|
2020
Q4 | $15.3M | Buy |
246,862
+219,130
| +790% | +$12.5M | ﹤0.01% | 2113 |
|
|
2020
Q3 | $1.65M | Sell |
27,732
-41,518
| -60% | -$2.83M | ﹤0.01% | 5088 |
|
|
2020
Q2 | $4.83M | Sell |
69,250
-32,861
| -32% | -$2.08M | ﹤0.01% | 3134 |
|
|
2020
Q1 | $4.63M | Buy |
102,111
+38,312
| +60% | +$2.17M | ﹤0.01% | 2829 |
|
|
2019
Q4 | $4.15M | Buy |
63,799
+25,167
| +65% | +$1.68M | ﹤0.01% | 3309 |
|
|
2019
Q3 | $2.4M | Buy |
38,632
+7,694
| +25% | +$483K | ﹤0.01% | 4194 |
|
|
2019
Q2 | $2.2M | Sell |
30,938
-75,662
| -71% | -$5.57M | ﹤0.01% | 4353 |
|
|
2019
Q1 | $8.36M | Buy |
106,600
+3,206
| +3% | +$243K | ﹤0.01% | 2282 |
|
|
2018
Q4 | $8.75M | Buy |
103,394
+38,633
| +60% | +$4.12M | ﹤0.01% | 2061 |
|
|
2018
Q3 | $11.1M | Buy |
64,761
+13,625
| +27% | +$2.05M | ﹤0.01% | 1977 |
|
|
2018
Q2 | $6.61M | Buy |
51,136
+24,686
| +93% | +$2.75M | ﹤0.01% | 2412 |
|
|
2018
Q1 | $2.73M | Buy |
26,450
+17,633
| +200% | +$1.74M | ﹤0.01% | 3270 |
|
|
2017
Q4 | $753K | Sell |
8,817
-1,923
| -18% | -$167K | ﹤0.01% | 5064 |
|
|
2017
Q3 | $912K | Buy |
10,740
+4,168
| +63% | +$330K | ﹤0.01% | 4446 |
|
|
2017
Q2 | $498K | Sell |
6,572
-1,283
| -16% | -$89.8K | ﹤0.01% | 5115 |
|
|
2017
Q1 | $519K | Sell |
7,855
-9,297
| -54% | -$612K | ﹤0.01% | 4958 |
|
|
2016
Q4 | $1.09M | Sell |
17,152
-5,290
| -24% | -$334K | ﹤0.01% | 3736 |
|
|
2016
Q3 | $1.43M | Sell |
22,442
-1,763
| -7% | -$129K | ﹤0.01% | 3387 |
|
|
2016
Q2 | $1.8M | Buy |
24,205
+13,785
| +132% | +$1.02M | ﹤0.01% | 2864 |
|
|
2016
Q1 | $696K | Buy |
10,420
+642
| +7% | +$39K | ﹤0.01% | 3943 |
|
|
2015
Q4 | $661K | Sell |
9,778
-5,290
| -35% | -$327K | ﹤0.01% | 4109 |
|
|
2015
Q3 | $805K | Sell |
15,068
-1,443
| -9% | -$87.6K | ﹤0.01% | 4116 |
|
|
2015
Q2 | $1.04M | Buy |
16,511
+4,488
| +37% | +$245K | ﹤0.01% | 3914 |
|
|
2015
Q1 | $578K | Sell |
12,023
-4,969
| -29% | -$190K | ﹤0.01% | 4697 |
|
|
2014
Q4 | $564K | Buy |
16,992
+5,290
| +45% | +$172K | ﹤0.01% | 4558 |
|
|
2014
Q3 | $343K | Sell |
11,702
-2,244
| -16% | -$74.5K | ﹤0.01% | 5100 |
|
|
2014
Q2 | $542K | Sell |
13,946
-3,206
| -19% | -$130K | ﹤0.01% | 4289 |
|
|
2014
Q1 | $720K | Buy |
+17,152
| New | +$715K | ﹤0.01% | 3842 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Citadel Advisors's LGND Position: Q1 2026 in Review
Citadel Advisors increased its Ligand Pharmaceuticals (LGND) stake by 219% in Q1 2026, buying an estimated $896K and bringing the position to 6,596 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7037.
Citadel Advisors first reported a position in LGND in Q3 2013 and has held it in 43 quarters since. The position peaked at $21.6M in Q3 2020. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Citadel Advisors held 6,596 shares of Ligand Pharmaceuticals worth $1.32M as of Q1 2026.
- Citadel Advisors bought 4,530 Ligand Pharmaceuticals shares in Q1 2026, an estimated $896K.
- Ligand Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7037 holding.
- Citadel Advisors first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Citadel Advisors's Ligand Pharmaceuticals position peaked at $21.6M in Q3 2020.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.